Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior

Neuropsychopharmacology

Volumn 41, Issue 3, 2016, Pages 686-694

  Yohn, Samantha E ^a   Collins, Samantha L ^a   Contreras Mora, Hector M ^a   Errante, Emily L ^a   Rowland, Margaret A ^a   Correa, Merce ^b   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITAT JAUME I   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; ECOPIPAM; FLUOXETINE; HALOPERIDOL; TETRABENAZINE; VANOXERINE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER UPTAKE INHIBITOR; PIPERAZINE DERIVATIVE; SLC18A2 PROTEIN, RAT; VESICULAR MONOAMINE TRANSPORTER;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; COMPARATIVE STUDY; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DECISION MAKING; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOTIVATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAZEPINES; BUPROPION; CHOICE BEHAVIOR; DESIPRAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HALOPERIDOL; MALE; MOTIVATION; NEUROTRANSMITTER UPTAKE INHIBITORS; PIPERAZINES; RATS, SPRAGUE-DAWLEY; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84953924611     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.188     Document Type: Article

References (54)

1. Anderson PH (1989). The dopamine inhibitor GBR 12909: Selectivity and molecular mechanism of action. Eur J Pharmacol 166: 504.
2. Armario A, Gavaldà A, Martí O (1988). Forced swimming test in rats: Effect of desipramine administration and the period of exposure to the test on struggling behavior, swimming, immobility and defecation rate. Eur J Pharmacol 158: 207-212.
3. Bell DS, Shipman WM, Cleves MA, Siegelman J (2013). Which drug for which patient? Is there a fluoxetine responding versus a bupropion responding personality profile? Clin Pract Epidemiol Ment Health 9: 142-147.
4. Carr GV, Lucki I (2011). The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology 213: 265-287.
5. Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012). Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin Ther 34: 1487-1504.
6. Cooper JA, Tucker VL, Papakostas GI (2014). Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol 28: 118-124.
7. Cuthbert BN, Insel TR (2013). Toward the future of psychiatric diagnosis: The seven pillars of RDoC. BMC Med 11: 126.
8. Demyttenaere K, De Fruyt J, Stahl SM (2005). The many faces of fatigue in major depressive disorder. J Neuropsychopharmacol 8: 93-105.
9. Esumi S, Sagara H, Nakamoto A, Kawasaki Y, Gomita Y, Sendo T (2013). Effect of GBR12909 on affective behavior: Distinguishing motivational behavior from antidepressant-like and addictionlike behavior using the runway model of intracranial selfstimulation. Behav Brain Res 243: 313-321.
10. Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P et al (2014). Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety 31: 250-257.
11. Floresco SB, Tse MT, Ghods-Sharifi S (2008). Dopaminergic and glutamatergic regulation of effort-and delay-based decision making. Neuropsychopharmacology 33: 1966-1979.
12. Frank S (2010). Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 6: 657-665.
13. Gullion CM, Rush AJ (1998). Toward a generalizable model of symptoms in major depressive disorder. Biol Psychiatry 44: 959-972.
14. Hosking JG, Floresco SB, Winstanley CA (2015). Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: A comparison of two rodent cost/benefit decisionmaking tasks. Neuropsychopharmacology 40: 1005-1015.
15. Hudson AL, Lalies MD, Silverstone P (2012). Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex. Canadian J Physiol Pharmacol 90: 803-809.
16. Jang DP, Lee SH, Park CW, Lee SY, Kim YB, Cho ZH (2009). Effects of fluoxetine on the rat brain in the forced swimming test: A [F-18]FDG micro-PET imaging study. Neurosci Lett 451: 60-64.
17. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N et al (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29: 566-579.
18. Keppel G (1991). Design and Analysis: A Researcher's Handbook. Prentice-Hall: Upper Saddle River, NJ.
19. Mai B, Sommer S, Hauber W (2012). Motivational states influence effort-based decision making in rats: The role of dopamine in the nucleus accumbens. Cogn Affect Behav Neurosci 12: 74-84.
20. McGinty VB, Lardeux S, Taha SA, Kim JJ, Nicola SM (2013). Invigoration of reward seeking by cue and proximity encoding in the nucleus accumbens. Neuron 78: 910-922.
21. Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J et al (2009). The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost-benefit procedure. Psychopharmacology 204: 103-112.
22. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR et al (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR∗D report. Psychol Med 40: 41-50.
23. Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y et al (2013). Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: Implications for animal models of the motivational symptoms of depression. J Neurosci 33: 19120-19130.
24. Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA et al (2014). Effort-related motivational effects of the proinflammatory cytokine interleukin 1-beta: Studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology 231: 727-736.
25. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL et al (2007). The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol 21: 461-471.
26. Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH (2012). Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann Pharmacother 46: E8.
27. Papakostas GI, Nutt DJ, Hallet LA, Tucker VL, Krishen A, Fava M (2006). Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 15: 1350-1355.
28. Pardo M, López-Crus L, Miguel NS, Salamone JD, Correa M (2015). Selection of sucrose concentration depends on the effort required to obtain it: Studies using tetrabenazine, D1, D2, D3 receptor antagonists. Psychopharmacology 232: 2377-2391.
29. Podurgiel SJ, MilliganMN, Yohn SE, Purcell LJ, Contreras-Mora HM, Correa M et al (2015). Fluoxetine administration exacerbates oral tremor and striatal dopamine depletion in a rodent pharmacological model of parkinsonism. Neuropsychopharmacology 40: 2240-2247.
30. Pizzagalli DA (2014). Depression, stress, and anhedonia: Toward a synthesis and integrated model. Annu Rev Clin Psychol 10: 393-423.
31. Randall PA, Pardo M, Nunes EJ, López Cruz L, Vemuri VK, Makriyannis A et al (2012). Dopaminergic modulation of effortrelated choice behavior as assessed by a progressive ratio chow feeding choice task: Pharmacological studies and the role of individual differences. PLoS One 7: E47934.
32. Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B et al (2014). The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: Reversal with antidepressant drugs. PLoS One 9: E99320.
33. Randall PA, Lee CA, Podurgiel SJ, Hart E, Yohn SE, Jones M et al (2015). Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treatment of effort-related motivational symptoms. Int J Neuropsychopharmacol 18: 1-11.
34. Robbins TW, Everitt BJ (2007). The role for mesencephalic dopamine in activation: Commentary on Berridge. Psychopharmacology (Berl) 191: 433-437.
35. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M (2014). The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry 55: 1-10.
36. Salamone JD, Correa M (2002). Motivational views of reinforcement: Implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137: 3-25.
37. Salamone JD, Correa M (2012). The mysterious motivational functions of mesolimbic dopamine. Neuron 76: 470-485.
38. Salamone JD, Correa M, Mingote S, Weber SM (2003). Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: Implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 305: 1-8.
39. Salamone JD, Correa M, Farrar A, Mingote SM (2007). Effortrelated functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 191: 461-482.
40. Sanders AC, Hussain AJ, Hen R, Zhuang X (2007). Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology 32: 2321-2329.
41. Schweimer J, Saft S, Hauber W (2005). Involvement of catecholamine neurotransmission in the rat anterior cingulate in effortrelated decision making. Behav Neurosci 119: 1687-1692.
42. Schweimer J, Hauber W (2006). Dopamine D1 receptors in the anterior cingulate cortex regulate effort-related decision making. Learn Mem 13: 777-782.
43. Shafiei N, Gray M, Viau V, Floresco SB (2012). Acute stress induces selective alterations in cost/benefit decision-making. Neuropsychopharmacology 37: 2194-2209.
44. Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008). Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology 196: 565-574.
45. Stahl SM (2002). The psychopharmacology of energy and fatigue. J Clin Psychiatry 63: 7-8.
46. Stotz G,Woggon B, Angst J (1998). Psychostimulants in the therapy of treatment-resistant depression. Dialogues Clin Neurosci 1: 165-174.
47. Stenman E, Lilja A (2013). Increased monoaminergic neurotransmission improves compliance with physical activity recommendations in depressed patients with fatigue. Med Hypotheses 80: 47-49.
48. Tadano T, Nakagawasai O, Jiijima F, Tan-No K, Kisara K (2000). The effects of traditional tonics on fatigue in mice differ from those of the antidepressant imipramine: A pharmacological and behavioral study. Am J Chin Med 28: 97-104.
49. Treadway MT, Zald DH (2011). Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neurosci Biobehav Rev 35: 537-555.
50. Treadway MT, Bossaller NA, Shelton RC, Zald DH (2012). Effortbased decision-making in major depressive disorder: A translational model of motivational anhedonia. J Abnorm Psychol 121: 553-558.
51. Tylee A, Gastpar M, Lépine JP, Mendlewicz J (1999). Identification of depressed patient types in the community and their treatment needs: Findings from the DEPRES II (Depression Research in European Society II) survey. Int Clin Psychopharmacol 14: 153-165.
52. Wang H, Chen X, Li Y, Tang TS, Bezprozvanny I (2010). Tetrabenazine is neuroprotective in Huntington's diseasemice. Mol Neurodegener 5: 18.
53. Yamada J, Sugimoto Y, Yamada S (2004). Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 504: 207-211.
54. Yohn SE, Thompson C, Randall PA, Lee CA, Müller CE, Bagi Y et al (2015). The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: Reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology 232: 1313-1323.